IDEAYA Biosciences, Inc.
No SEC Form 4 filings for $IDYA in the last 30 days.
See all $IDYA insider activity →IDEAYA Biosciences (IDYA) reported a widened quarterly net loss but maintains strong liquidity with $1.24B in cash. It dosed the first patient in a Phase 3 trial for darovasertib in uveal melanoma, sharing costs with partner Servier. The company is advancing its oncology pipeline while managing R&D costs, with regulatory approvals and commercial execution being key to its success.
IDEAYA Biosciences (IDYA) and Servier began a global Phase 3 trial (OptimUM-11) for darovasertib + crizotinib as adjuvant therapy for high-risk uveal melanoma. The trial aims to enroll 450 patients, with relapse-free survival as the primary endpoint. IDEAYA holds U.S. rights, Servier holds international rights. IDYA stock is up 0.41% in pre-market trading.
IDEAYA Biosciences (IDYA) announced a successful FDA meeting finalizing the Phase 3 trial design for IDE849, its DLL3-targeting ADC, in extensive stage small cell lung cancer. The trial, starting by year-end 2026, aims for accelerated and full approval with 400 patients. IDE849 is also being evaluated in combination studies. IDYA's stock closed at $40.11, down 3.97%.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning IDYA (IDEAYA Biosciences, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent IDYA coverage spans technology, financial news and regulation.
First dosing could trigger short‑squeeze potential and boost sentiment if trial data are positive.
Positive trial initiation may lift sentiment and attract speculative buying.
The FDA meeting clears a path for a pivotal Phase 3 trial, potentially unlocking accelerated approval.
Collaboration with a Roche unit adds credibility and potential future revenue.
The partnership could boost IDEAYA's pipeline value and attract investor interest, but clinical outcomes remain uncertain.
AlphAI scores every news story that mentions IDYA with an AI model for sentiment and relevance, and aggregates insider trades from IDEAYA Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
IDEAYA Biosciences (IDYA) reported a widened quarterly net loss but maintains strong liquidity with $1.24B in cash. It dosed the first patient in a Phase 3 trial for darovasertib in uveal melanoma, sharing costs with partner Servier. The company is advancing its oncology pipeline while managing R&D costs, with regulatory approvals and commercial execution being key to its success.
3 min readIDEAYA Biosciences (IDYA) and Servier began a global Phase 3 trial (OptimUM-11) for darovasertib + crizotinib as adjuvant therapy for high-risk uveal melanoma. The trial aims to enroll 450 patients, with relapse-free survival as the primary endpoint. IDEAYA holds U.S. rights, Servier holds international rights. IDYA stock is up 0.41% in pre-market trading.
2 min readIDEAYA Biosciences (IDYA) announced a successful FDA meeting finalizing the Phase 3 trial design for IDE849, its DLL3-targeting ADC, in extensive stage small cell lung cancer. The trial, starting by year-end 2026, aims for accelerated and full approval with 400 patients. IDE849 is also being evaluated in combination studies. IDYA's stock closed at $40.11, down 3.97%.
2 min readUltragenyx (RARE) and Regeneron (REGN) received FDA approvals for GENGLYCOS and Pasatru, respectively. BioMarin (BMRN) acquired Alesta for $490M. Humacyte (HUMA) and Eyepoint (EYPT) faced trial setbacks. Key financials: RARE -$25.32, REGN -$826.64, BMRN -$67.68, HUMA -$0.68.
3 min readIDEAYA Biosciences (IDYA) and Genentech (part of Roche) will collaborate on a clinical trial to evaluate IDE892, IDEAYA's PRMT5 inhibitor, in combination with Genentech's KRAS G12D inhibitor, RG6620, for pancreatic cancer patients with MTAP deletions and KRAS G12D mutations. Genentech will sponsor the trial, and IDEAYA will supply IDE892. IDE892 has shown potential best-in-class properties, including selective binding and favorable drug-like properties. The companies will retain commercial right
2 min readIDEAYA Biosciences, Inc. (IDYA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update • Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint; new drug application (NDA) filing is underway
6 min readSOUTH SAN FRANCISCO, Calif., July 31, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on July 30, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 260,200 shares of the Company's common stock to fourteen newly hired employees.
1 min readIDEAYA Biosciences (NASDAQ: IDYA) said it initiated Part 2 monotherapy expansion in its Phase 1/2 trial of IDE892, a PRMT5 inhibitor for MTAP-deleted PDAC and NSCLC. The company reported projected efficacious target exposures and that the MTD has not been reached. IDE892 and IDE397 combination escalation continues, and a Roche RG6505 combo is in collaboration.
2 min readIDEAYA Biosciences (Nasdaq: IDYA) said it will present three ESMO 2026 abstracts in Madrid on darovasertib and IDE849. Darovasertib data will cover Phase 2/3 OptimUM-02 (HLA*A2:01-negative metastatic uveal melanoma), Phase 2 OptimUM-01 (HLA*A2:01-positive), and Phase 2 OptimUM-09 (neoadjuvant). Partner Hengrui will present long-term Phase 1 IDE849 (SHR-4849) results in relapsed SCLC and NECs.
2 min readIDEAYA Biosciences, Inc. (IDYA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001676725 0001676725 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16,
3 min read
